Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (NYSE American: MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: January 6, 2025
Reporting Period: Fiscal year ended December 31, 2024
The Company received a deficiency letter from NYSE American on January 6, 2025, stating it failed to hold an annual meeting of stockholders during its fiscal year ended December 31, 2024, as required by Section 704 of the NYSE American Company Guide.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing compliance. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Listing Status: The Company's common stock will continue to be listed and traded on the NYSE American during the applicable cure period.
- Compliance Indicator: The stock will be assigned a ".BC" indicator by the NYSE to signify the Company is below compliance with listing standards.
- Remediation Plan: The Company intends to hold its annual meeting no later than December 31, 2025, to regain compliance.
Guidance, Outlook, and Risks
Management Commentary: The Company states the notice has no immediate impact on the listing of its common stock. The ".BC" indicator will be removed once the Company is deemed compliant.
Risks and Contingencies: The filing includes forward-looking statements subject to risks and uncertainties, including:
- The sale of MAT 2203.
- The evaluation of other alternatives for the Company, including a winddown or dissolution.
- The fact that all product candidates are in a development stage and are not available for sale or use.
Investor Verification Checklist
- Verify the date and agenda of the upcoming annual meeting of stockholders to ensure it occurs by December 31, 2025.
- Monitor the stock ticker for the ".BC" compliance indicator on the NYSE American.
- Review recent press releases (Exhibit 99.1) for details on the sale of MAT 2203 or potential winddown/dissolution plans.
- Check subsequent filings for updates on the Company's compliance status with the NYSE American Company Guide.